New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 15, 2013
11:14 EDTTSRX, ZIOP, EGLE, FSL, IRBTHigh option volume stocks: TSRX FSL ZIOP IRBT EGLE
News For TSRX;FSL;ZIOP;IRBT;EGLE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
09:05 EDTFSLNXP Semiconductors to hold a conference call
Subscribe for More Information
November 27, 2015
07:01 EDTFSLNXP Semiconductors receives Chinese approval for Freescale merger
Subscribe for More Information
November 25, 2015
16:32 EDTFSLNXP Semiconductors receives FTC approval for merger with Freescale
Subscribe for More Information
15:24 EDTFSLFTC requires NXP Semiconductors to divest RF power amplifier assets
Subscribe for More Information
08:36 EDTIRBTiRobot management to meet with Benchmark
Subscribe for More Information
November 19, 2015
07:07 EDTZIOPZIOPHARM announces data highlighting Ad-RTS-hIL-12 activity in Glioma
ZIOPHARM Oncology announced that the company is presenting initial results from an ongoing Phase 1 dose-escalation study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma or grade III malignant glioma. The presentation, titled "Intratumoral Regulated Expression of IL-12 as a Gene Therapy Approach to Treatment of Glioma," will be delivered at 5:15 pm CT, Saturday, November 21, 2015 at the 20th Annual Society for Neuro-Oncology, or SNO, Annual Scientific Meeting in San Antonio, Texas. Ad-RTS-hIL-12 + the oral activator veledimex is a novel viral gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T-cell immune response. The ongoing multi-center Phase 1 trial of Ad-RTS-hIL-12 + veledimex examines a gene therapy strategy for recurrent high grade gliomas, with the goal of generating a localized anti-tumor immune response. The primary objective of the study is to determine the safety and tolerability of a single intra-tumoral Ad-RTS-hIL-12 injection activated upon dosing with oral veledimex. Secondary objectives are to determine the Ad-RTS-hIL-12 + veledimex maximum tolerated dose, the immune responses elicited by Ad-RTS-hIL-12 + veledimex, and assessment of biologic response. The study is expected to enroll up to 72 subjects. Preclinically, the effects of Ad-RTS-mIL-12 + veledimex were studied in orthotopic glioma animal models, demonstrating veledimex crossed the blood-brain-barrier. In a standard orthotopic glioma mouse model that evaluated dexamethasone, bevacizumab, temozolamide and a PD-1 inhibitor, Ad-RTS-mIL-12 + veledimex demonstrated a dramatic dose-related increase in survival, without significant adverse events, that was superior to all other treatments. In the current, on-going Phase 1 study, five patients are available for initial assessment, two with recurrent grade III malignant glioma and three with grade IV. Results show IL-12 was detectable in peripheral blood along with downstream IFNg, indicating that veledimex crossed the blood brain barrier activating IL-12 expression from intra-tumorally administered Ad-RTS-hIL-12. Ad-RTS-hIL-12 + veledimex was well tolerated with minimal neurologic toxicity. The most common adverse events were headache, fever, hyponatremia and nausea/vomiting. Related serious adverse events were aseptic meningitis, neutropenia, thrombocytopenia, leukopenia, with all toxicity to date consistent with the "on-target" effects of immunotherapy.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use